Literature DB >> 18311852

A mixed approach for proving non-inferiority in clinical trials with binary endpoints.

Valentin Rousson1, Burkhardt Seifert.   

Abstract

When a new treatment is compared to an established one in a randomized clinical trial, it is standard practice to statistically test for non-inferiority rather than for superiority. When the endpoint is binary, one usually compares two treatments using either an odds-ratio or a difference of proportions. In this paper, we propose a mixed approach which uses both concepts. One first defines the non-inferiority margin using an odds-ratio and one ultimately proves non-inferiority statistically using a difference of proportions. The mixed approach is shown to be more powerful than the conventional odds-ratio approach when the efficacy of the established treatment is known (with good precision) and high (e.g. with more than 56% of success). The gain of power achieved may lead in turn to a substantial reduction in the sample size needed to prove non-inferiority. The mixed approach can be generalized to ordinal endpoints.

Mesh:

Substances:

Year:  2008        PMID: 18311852     DOI: 10.1002/bimj.200710410

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  6 in total

1.  Methods for equivalence and noninferiority testing.

Authors:  Gisela Tunes da Silva; Brent R Logan; John P Klein
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

2.  Non-inferiority Testing for Risk Ratio, Odds Ratio and Number Needed to Treat in Three-arm Trial.

Authors:  Shrabanti Chowdhury; Ram C Tiwari; Samiran Ghosh
Journal:  Comput Stat Data Anal       Date:  2018-09-15       Impact factor: 1.681

3.  Bayesian Approach for Assessing Non-inferiority in Three-arm Trials for Risk Ratio and Odds Ratio.

Authors:  Shrabanti Chowdhury; Ram C Tiwari; Samiran Ghosh
Journal:  Stat Biopharm Res       Date:  2019-04-22       Impact factor: 1.452

4.  Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY.

Authors:  Sylvia Haas; Sebastian M Schellong; Ulrich Tebbe; Horst-Eberhard Gerlach; Rupert Bauersachs; Nima Melzer; Claudia Abletshauser; Christian Sieder; Peter Bramlage; Hanno Riess
Journal:  BMC Cancer       Date:  2011-07-26       Impact factor: 4.430

5.  Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.

Authors:  J Wason; A Marshall; J Dunn; R C Stein; N Stallard
Journal:  Br J Cancer       Date:  2014-03-25       Impact factor: 7.640

6.  Choosing and changing the analysis scale in non-inferiority trials with a binary outcome.

Authors:  Zhong Li; Matteo Quartagno; Stefan Böhringer; Nan van Geloven
Journal:  Clin Trials       Date:  2021-10-24       Impact factor: 2.486

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.